Browse Studies — Arctuva

Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with …

Retinitis PigmentosaChoroideremiaStargardt Macular Dystrophy+4 more

Estimated

~$10 – $1,050

Ray Therapeutics, Inc.NCT06375239

Phase 1

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjec…

Stargardt DiseaseStargardt Macular DegenerationStargardt Macular Dystrophy

Estimated

~$10 – $7,500

Splice BioNCT06942572

A Prospective Observational Study to Assess the Reliability and Validity of the Multi-Luminance Shape Discrimination Test (MLSDT) With 9 Objects

The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vis…

Macular DegenerationGeographic AtrophyStargardt Disease

Estimated

~$10 – $1,050

Nanoscope Therapeutics Inc.NCT06805474

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Ge…

StargardtStargardt's DiseaseStargardt Disease+1 more

Estimated

~$10 – $1,125

Splice BioNCT06435000